Research News

New Guidelines on Risk, Genetic Counseling & Testing for BRCA-related Cancer

(December 30, 2013)   The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of... 

High Volume Hospitals and Providers Improve Survival

(December 20, 2013)  Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival.  The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian... 

New OCRF Research on Ovarian Cancer Proliferation, Migration, and Response to Therapy

Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp,... 

OCRF Research Sheds Light on Ovarian Cancer Origins in BRCA Mutation Carriers

A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers. ... 

OCRF Research Shows that Combining Targeted Agents is Effective Against Ovarian Cancer

New research funded in part by OCRF has shown that combining microRNA and siRNAs may be an effective new approach to developing better targeted therapies for ovarian cancer.  The research was reported in the November 2013 issue of Cancer Discovery, where the findings were also highlighted in an editorial... 

Use of a Chemoresponse Assay Improves Clinical Outcomes

Research published in the November 2013 issue of Gynecologic Oncology reports that the use of the chemoresponse assay ChemoFx can lead to improved clinical outcomes for women undergoing treatment for ovarian cancer. The goal of this clinical trial, which took nearly ten years to complete, was to determine... 

Quality of life: Primary Debulking Surgery versus Neo-adjuvant Chemotherapy

An international group of researchers examined quality of life factors for ovarian cancer patients enrolled in a large European clincial trial (EORTC 55971).  They compared the quality of life patients who had primary debulking surgery versus those who had neo-adjuvant chemotherapy, followed by surgery. The... 

DNA “Tags” Could Guide Treatment

A new study conducted by Cancer Research UK has identified chemical “tags” on DNA in patients’ tumors that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive.  The research was published in Clinical Cancer Research. These tags, known as epigenetic... 

Ovarian Cancer News from the European Cancer Congress

The European Cancer Congress convened in Amsterdam, the Netherlands from September 27 – October 1, 2013.  The European Cancer Congress in the main multidisciplinary and multi-professional educational meeting in oncology to take place in Europe. At ECCO, cancer specialists from around the world convene... 

Association between Marriage Status and Improved Cancer Outcomes

Research published in Sept. 2013 in the Journal of Clinical Oncology show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. The results, based on a large retrospective study of the National Cancer Institute’s SEER database, also...